Back to today’s briefing

Story perspectives

FDA Approves Zepbound: Breakthrough for Sleep Apnea and Obesity

1/30/2025

40 9

Summary

Story summary

The FDA has made a groundbreaking decision by approving Zepbound, the first-ever medication designed for adults battling both moderate-to-severe obstructive sleep apnea and obesity. This innovative GLP-1 drug not only aids in weight loss but also holds promise for alleviating apnea symptoms. While CPAP therapy remains the gold standard, Zepbound opens new doors for those struggling with weight-related issues.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving Zepbound, the first-ever medication designed for adults battling both moderate-to-severe obstructive sleep apnea and obesity. This innovative GLP-1 drug not only aids in weight loss but also holds promise for alleviating apnea symptoms. While CPAP therapy remains the gold standard, Zepbound opens new doors for those struggling with weight-related issues.